Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY W MATTINGLEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1215933379
CMS profile
236102
Location
SAINT CHARLES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$601,325.30

722 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 15; records 251–300 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY W MATTINGLEY

NPI 1215933379 · CMS profile ID 236102

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

SAINT CHARLES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 15; records 251–300 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY W MATTINGLEY, NPI 1215933379, CMS profile ID 236102. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 15; records 251–300 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). GREGORY W MATTINGLEY, NPI 1215933379, CMS profile ID 236102. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 15; records 251–300 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
GREGORY W MATTINGLEY, NPI 1215933379, CMS profile ID 236102, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 15; records 251–300 of 722 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215933379?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

722 matching records · $601,325.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 722 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 722.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neuronetics, Inc. $15.7308/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686645105 CMS
Otsuka America Pharmaceutical, Inc. $2,688.0008/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433075 CMS
Alkermes, Inc. $84.8108/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686608733 CMS
Otsuka America Pharmaceutical, Inc. $2,184.0008/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433073 CMS
Allergan Inc. $4.1108/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670784021 CMS
Ironshore Pharmaceuticals Inc. $4,080.0008/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707558041 CMS
Ironshore Pharmaceuticals Inc. $2,640.0008/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707558043 CMS
Ironshore Pharmaceuticals Inc. $1,200.0008/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707558045 CMS
Supernus Pharmaceuticals, Inc. $30.0008/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330449 CMS
Supernus Pharmaceuticals, Inc. $225.4608/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330453 CMS
Supernus Pharmaceuticals, Inc. $266.6808/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330455 CMS
Supernus Pharmaceuticals, Inc. $375.0008/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330459 CMS
Supernus Pharmaceuticals, Inc. $445.6208/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330461 CMS
Supernus Pharmaceuticals, Inc. $3,500.0008/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330465 CMS
Supernus Pharmaceuticals, Inc. $2,500.0008/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330443 CMS
Supernus Pharmaceuticals, Inc. $295.4808/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702330447 CMS
Takeda Pharmaceuticals U.S.A., Inc. $445.9608/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681905652 CMS
Ironshore Pharmaceuticals Inc. $131.3008/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707559781 CMS
Ironshore Pharmaceuticals Inc. $131.2908/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707559783 CMS
Ironshore Pharmaceuticals Inc. $131.2908/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707559785 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.8608/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682040367 CMS
Ironshore Pharmaceuticals Inc. $154.2208/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707560485 CMS
Ironshore Pharmaceuticals Inc. $22.3808/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707560487 CMS
Ironshore Pharmaceuticals Inc. $136.9108/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707560489 CMS
Neos Therapeutics, LP $9.6008/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705603489 CMS
Allergan Inc. $8.8308/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670784015 CMS
Otsuka America Pharmaceutical, Inc. $215.5808/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433067 CMS
Otsuka America Pharmaceutical, Inc. $215.5808/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433069 CMS
Otsuka America Pharmaceutical, Inc. $215.5808/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433071 CMS
Shire North American Group Inc $16.0908/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637874749 CMS
Janssen Pharmaceuticals, Inc $4,080.0008/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658995399 CMS
Janssen Pharmaceuticals, Inc $214.1408/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658995403 CMS
Janssen Pharmaceuticals, Inc $14.9008/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658995407 CMS
Otsuka America Pharmaceutical, Inc. $212.4308/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433055 CMS
Otsuka America Pharmaceutical, Inc. $404.9108/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433057 CMS
Otsuka America Pharmaceutical, Inc. $33.2808/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433059 CMS
Otsuka America Pharmaceutical, Inc. $212.4208/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433061 CMS
Otsuka America Pharmaceutical, Inc. $404.9108/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433063 CMS
Otsuka America Pharmaceutical, Inc. $120.2208/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433065 CMS
Ironshore Pharmaceuticals Inc. $5.0008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707563245 CMS
Ironshore Pharmaceuticals Inc. $46.1008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707563247 CMS
Ironshore Pharmaceuticals Inc. $5.0008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707563249 CMS
Ironshore Pharmaceuticals Inc. $46.1008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707563251 CMS
Ironshore Pharmaceuticals Inc. $46.1008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707563253 CMS
Ironshore Pharmaceuticals Inc. $5.0008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707563255 CMS
Otsuka America Pharmaceutical, Inc. $212.4308/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433049 CMS
Otsuka America Pharmaceutical, Inc. $404.9108/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433051 CMS
Otsuka America Pharmaceutical, Inc. $122.1308/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687433053 CMS
Sunovion Pharmaceuticals Inc. $16.4308/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688152145 CMS
Vanda Pharmaceuticals Inc. $19.1708/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697655723 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $601,325.30 722
PY2020 $300,094.05 265
PY2021 $540,439.79 551
PY2022 $558,389.91 648
PY2023 $857,162.62 779
PY2024 $842,174.58 832
PY2025 $1,012,688.07 883

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $385,511.93 71
PY2024 Principal investigator $1,002,661.79 106
PY2023 Principal investigator $569,554.84 100
PY2022 Principal investigator $243,940.43 72
PY2021 Principal investigator $384,699.58 89
PY2020 Principal investigator $602,612.63 82
PY2019 Principal investigator $303,620.29 105

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,445.60 12/31/2025 Non-covered Recipient Entity
SAINT CHARLES PSYCHIATRIC ASSOCIATES AND MIDWEST RESEARCH GROUP
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202534249
Principal investigator 1 Axsome Therapeutics, Inc. $400.00 12/11/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916366
Principal investigator 1 Alkermes, Inc. $3,300.00 12/03/2025 Non-covered Recipient Entity
ST. CHARLES PSYCHIATRIC ASSOCIATES
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613986
Principal investigator 1 ABBVIE INC. $237.64 11/25/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202525366
Principal investigator 1 Boehringer Ingelheim International GmbH $1,950.00 11/17/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695421
Principal investigator 1 Axsome Therapeutics, Inc. $400.00 11/14/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916364
Principal investigator 1 Corium, LLC $3,500.00 11/13/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181950042
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,214.83 11/07/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232946880
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/20/2025 Non-covered Recipient Entity
St Charles Psychc Associates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175237482
Principal investigator 1 ABBVIE INC. $3,299.73 10/09/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202516381
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695417
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695419
Principal investigator 1 ABBVIE INC. $5,000.00 09/12/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202510846
Principal investigator 1 ABBVIE INC. $5,939.00 09/10/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202510446
Principal investigator 1 ABBVIE INC. $3,299.73 09/04/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202509086
Principal investigator 1 Corium, LLC $3,375.66 09/03/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949996
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 08/22/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695415
Principal investigator 1 Vanda Pharmaceuticals Inc. $12,000.00 08/21/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232946139
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,500.00 08/15/2025 Non-covered Recipient Entity
MIDWEST RESEARCH GROUPST CHARLES PSYCHIATRIC ASSOC
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946127
Principal investigator 1 Vanda Pharmaceuticals Inc. $234.20 08/15/2025 Non-covered Recipient Entity
MIDWEST RESEARCH GROUPST CHARLES PSYCHIATRIC ASSOC
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946131
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,850.00 08/14/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES
ITI-007-421 No dispute reported 06/30/2026 1242356910
Principal investigator 1 Axsome Therapeutics, Inc. $5,209.05 08/13/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916362
Principal investigator 1 Vanda Pharmaceuticals Inc. $19,500.00 08/08/2025 Non-covered Recipient Entity
MIDWEST RESEARCH GROUPST CHARLES PSYCHIATRIC ASSOC
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946103
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 08/04/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695413
Principal investigator 1 Corium, LLC $1,473.96 07/29/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949994
Principal investigator 1 Axsome Therapeutics, Inc. $800.00 07/23/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916360
Principal investigator 1 Corium, LLC $3,346.17 07/10/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949992
Principal investigator 1 Janssen Research & Development, LLC $223.00 07/02/2025 Non-covered Recipient Entity
St Charles Psychc Associates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175237496
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 06/25/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695405
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 06/25/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695407
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695409
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695411
Principal investigator 1 Axsome Therapeutics, Inc. $2,573.50 06/13/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916358
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,739.63 05/28/2025 Non-covered Recipient Entity
Saint Charles Psychiatric Associates And Midwest Research Group
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1235994113
Principal investigator 1 Boehringer Ingelheim International GmbH $600.00 05/27/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695403
Principal investigator 1 Collegium Pharmaceutical, Inc. $14.58 05/22/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended?Release Capsules (HLD200) in Children Aged 4 to 5 Years with Attention Deficit Hyperactivity Disorder. No dispute reported 06/30/2026 1208627818
Principal investigator 1 Axsome Therapeutics, Inc. $190.00 05/16/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916354
Principal investigator 1 Axsome Therapeutics, Inc. $5,006.06 05/16/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916356
Principal investigator 1 Corium, LLC $9,102.69 04/24/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949950
Principal investigator 1 Janssen Research & Development, LLC $1,778.00 04/23/2025 Non-covered Recipient Entity
St Charles Psychc Associates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175237489
Principal investigator 1 Axsome Therapeutics, Inc. $5,364.96 04/16/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916350
Principal investigator 1 Axsome Therapeutics, Inc. $140.00 04/16/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916352
Principal investigator 1 Collegium Pharmaceutical, Inc. $47.42 04/10/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended?Release Capsules (HLD200) in Children Aged 4 to 5 Years with Attention Deficit Hyperactivity Disorder. No dispute reported 06/30/2026 1208627796
Principal investigator 1 ABBVIE INC. $15,000.00 04/03/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202472186
Principal investigator 1 Alkermes, Inc. $1,850.00 04/02/2025 Non-covered Recipient Entity
ST. CHARLES PSYCHIATRIC ASSOCIATES
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613239
Principal investigator 1 Janssen Research & Development, LLC $4,330.00 04/02/2025 Non-covered Recipient Entity
St Charles Psychc Associates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175237454
Principal investigator 1 Axsome Therapeutics, Inc. $6,044.71 03/24/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916348
Principal investigator 1 Corium, LLC $101,870.22 03/19/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949880
Principal investigator 1 Collegium Pharmaceutical, Inc. $12,900.00 03/06/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended?Release Capsules (HLD200) in Children Aged 4 to 5 Years with Attention Deficit Hyperactivity Disorder. No dispute reported 06/30/2026 1208627894
Principal investigator 1 Janssen Research & Development, LLC $3,436.00 02/24/2025 Non-covered Recipient Entity
St Charles Psychc Associates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175237472
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 02/21/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695399
Principal investigator 1 Boehringer Ingelheim International GmbH $9,500.00 02/21/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695401
Principal investigator 1 Alkermes, Inc. $10,542.00 02/20/2025 Non-covered Recipient Entity
ST. CHARLES PSYCHIATRIC ASSOCIATES
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208612795
Principal investigator 1 Corium, LLC $3,199.01 02/20/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949878
Principal investigator 1 Corium, LLC $18,411.42 02/20/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
An Efficacy and Safety Study w/ Azstarys in Children With ADHD No dispute reported 06/30/2026 1181949928
Principal investigator 1 Axsome Therapeutics, Inc. $4,216.85 02/18/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916346
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 02/14/2025 Non-covered Recipient Entity
St Charles Psychc Associates
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175237444
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $600.00 02/12/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242332926
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,500.00 02/06/2025 Non-covered Recipient Entity
St Charles Psychiatric Associates
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220816382
Principal investigator 1 Corium, LLC $7,030.87 02/05/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949876
Principal investigator 1 Corium, LLC $2,876.95 01/29/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1181949874
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,125.00 01/29/2025 Non-covered Recipient Entity
ST CHARLES PSYCHIATRIC ASSOCIATES INC
AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242329869
Principal investigator 1 Janssen Research & Development, LLC $3,489.00 01/24/2025 Non-covered Recipient Entity
St Charles Psychc Associates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175237462
Principal investigator 1 Axsome Therapeutics, Inc. $30.00 01/14/2025 Non-covered Recipient Entity
Midwest Research Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916344
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 01/10/2025 Non-covered Recipient Entity
Midwest Research Group
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220695423
Principal investigator 1 Alkermes, Inc. $17,156.90 01/01/2025 Non-covered Recipient Entity
ST. CHARLES PSYCHIATRIC ASSOCIATES
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208627003
Principal investigator 1 Alkermes, Inc. $19,633.04 01/01/2025 Non-covered Recipient Entity
ST. CHARLES PSYCHIATRIC ASSOCIATES
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208627035
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Midwest Research Group
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220695391
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Midwest Research Group
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220695393
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Midwest Research Group
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220695395
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Midwest Research Group
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220695397